Finally, Rab35 and PODXL have been found to be differentially expressed in several cancers: Rab35 is downregulated in several tumours, including renal carcinomas46, 50, whereas PODXL overexpression has been identified as a potent marker for highly aggressive and metastatic cancers with poor prognosis51, 52. Here, RAB35 is linked to neoplasm.